Clinical Trials

Bladder Cancer

At Lehigh Valley Health Network, we are committed to providing our patients and community with the best possible care and treatments. Our research scientists are integrated with our clinical departments for a comprehensive, collaborative approach to research. Have a question about clinical trials? Contact the Network Office of Research and Innovation at 610-402-9543.

Showing 7 of 7 Clinical Trials Related to Bladder Cancer

MSK 16-1428

A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin with Atezolizumab (MPDL3280A) in Patients with Metastatic and Muscle Invasive Bladder Cancer, Respectively

Doctor(s) Running This Study

A031702

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Doctor(s) Running This Study

A031501

Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Doctor(s) Running This Study

Alliance A031701

ALLIANCE A031701: A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE

Doctor(s) Running This Study

BMS-CA045-009

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible

Doctor(s) Running This Study

SWOG S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

Doctor(s) Running This Study